Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2025-12-26 @ 1:31 AM
Study NCT ID:
NCT03452033
Status:
COMPLETED
Last Update Posted:
2022-07-12
First Post:
2018-02-26
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
H-1337 Ophthalmic Solution Phase 1/2
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2021-07-13', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D005902', 'term': 'Glaucoma, Open-Angle'}, {'id': 'D005901', 'term': 'Glaucoma'}], 'ancestors': [{'id': 'D009798', 'term': 'Ocular Hypertension'}, {'id': 'D005128', 'term': 'Eye Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'shinakazora@dwti.co.jp', 'phone': '+81-52-218-8785', 'title': 'Shigenobu Nakazora', 'organization': 'D. Western Therapeutics Institute'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': '28 days', 'eventGroups': [{'id': 'EG000', 'title': 'H-1337 0.06%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.06%', 'otherNumAtRisk': 21, 'deathsNumAtRisk': 21, 'otherNumAffected': 9, 'seriousNumAtRisk': 21, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'H-1337 0.2%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.2%', 'otherNumAtRisk': 22, 'deathsNumAtRisk': 22, 'otherNumAffected': 9, 'seriousNumAtRisk': 22, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'H-1337 0.6%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.6%', 'otherNumAtRisk': 22, 'deathsNumAtRisk': 22, 'otherNumAffected': 14, 'seriousNumAtRisk': 22, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Vehicle', 'description': 'Vehicle (contains all components of the active formulation with the exception of H-1337)', 'otherNumAtRisk': 22, 'deathsNumAtRisk': 22, 'otherNumAffected': 4, 'seriousNumAtRisk': 22, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Eye disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 21, 'numEvents': 21, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 22, 'numEvents': 22, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 22, 'numEvents': 22, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 22, 'numEvents': 22, 'numAffected': 2}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (Unspecified)'}, {'term': 'General disorders and administration site conditiions', 'stats': [{'groupId': 'EG000', 'numAtRisk': 21, 'numEvents': 21, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 22, 'numEvents': 22, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 22, 'numEvents': 22, 'numAffected': 13}, {'groupId': 'EG003', 'numAtRisk': 22, 'numEvents': 22, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (Unspecified)'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Intraocular Pressure (IOP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '22', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}, {'value': '22', 'groupId': 'OG003'}]}, {'units': 'study eyes', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '22', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}, {'value': '22', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'H-1337 0.06%', 'description': 'H-1337 Ophthalmic Solution 0.06%'}, {'id': 'OG001', 'title': 'H-1337 0.2%', 'description': 'H-1337 Ophthalmic Solution 0.2%'}, {'id': 'OG002', 'title': 'H-1337 0.6%', 'description': 'H-1337 Ophthalmic Solution 0.6%'}, {'id': 'OG003', 'title': 'Vehicle', 'description': 'Vehicle (contains all components of the active formulation with the exception of H-1337)'}], 'classes': [{'categories': [{'measurements': [{'value': '-4.45', 'spread': '3.801', 'groupId': 'OG000'}, {'value': '-5.16', 'spread': '3.114', 'groupId': 'OG001'}, {'value': '-4.93', 'spread': '3.110', 'groupId': 'OG002'}, {'value': '-0.39', 'spread': '2.355', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and 28 days', 'description': 'Mean change in IOP from baseline on Day 28 (Time 0 + 4h)', 'unitOfMeasure': 'mm Hg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'typeUnitsAnalyzed': 'study eyes', 'denomUnitsSelected': 'study eyes', 'populationDescription': 'mmHg in the study eye'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '22', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}, {'value': '22', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'H-1337 0.06%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.06%'}, {'id': 'OG001', 'title': 'H-1337 0.2%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.2%'}, {'id': 'OG002', 'title': 'H-1337 0.6%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.6%'}, {'id': 'OG003', 'title': 'Vehicle', 'description': 'Vehicle (contains all components of the active formulation with the exception of H-1337)'}], 'classes': [{'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '28 days', 'description': 'Number of participants with treatment-emergent adverse events', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'H-1337 0.06%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.06%'}, {'id': 'FG001', 'title': 'H-1337 0.2%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.2%'}, {'id': 'FG002', 'title': 'H-1337 0.6%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.6%'}, {'id': 'FG003', 'title': 'Vehicle', 'description': 'Vehicle (contains all components of the active formulation with the exception of H-1337)'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numUnits': '21', 'numSubjects': '21'}, {'groupId': 'FG001', 'numUnits': '22', 'numSubjects': '22'}, {'groupId': 'FG002', 'numUnits': '22', 'numSubjects': '22'}, {'groupId': 'FG003', 'numUnits': '22', 'numSubjects': '22'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numUnits': '21', 'numSubjects': '21'}, {'groupId': 'FG001', 'numUnits': '22', 'numSubjects': '22'}, {'groupId': 'FG002', 'numUnits': '22', 'numSubjects': '22'}, {'groupId': 'FG003', 'numUnits': '22', 'numSubjects': '22'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG001', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG002', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG003', 'numUnits': '0', 'numSubjects': '0'}]}]}], 'typeUnitsAnalyzed': 'study eyes', 'recruitmentDetails': 'A total of 87 subjects were enrolled and randomized across 6 investigational sites in the United States.', 'preAssignmentDetails': 'During the screening phase (Screening and Baseline Visits), subjects washed out any current ocular hypotensive therapy according to the below schedule:\n\nMuscarinic agonists (eg, pilocarpine) and oral or topical carbonic anhydrase inhibitor (CAIs): ≥5 days Alpha adrenoceptor agonists: ≥5 weeks Beta-adrenoceptor antagonists: ≥6 weeks Prostaglandin analogues and combination drugs (use longest wash-out period of individual components): ≥6 weeks'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'BG000'}, {'value': '22', 'groupId': 'BG001'}, {'value': '22', 'groupId': 'BG002'}, {'value': '22', 'groupId': 'BG003'}, {'value': '87', 'groupId': 'BG004'}]}], 'groups': [{'id': 'BG000', 'title': 'H-1337 0.06%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.06%'}, {'id': 'BG001', 'title': 'H-1337 0.2%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.2%'}, {'id': 'BG002', 'title': 'H-1337 0.6%', 'description': 'H-1337 Ophthalmic Solution Concentration 0.6%'}, {'id': 'BG003', 'title': 'Vehicle', 'description': 'Vehicle (contains all components of the active formulation with the exception of H-1337)'}, {'id': 'BG004', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '61.1', 'spread': '13.58', 'groupId': 'BG000'}, {'value': '64.1', 'spread': '10.02', 'groupId': 'BG001'}, {'value': '67.4', 'spread': '11.72', 'groupId': 'BG002'}, {'value': '65.0', 'spread': '14.44', 'groupId': 'BG003'}, {'value': '64.5', 'spread': '12.53', 'groupId': 'BG004'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '13', 'groupId': 'BG001'}, {'value': '14', 'groupId': 'BG002'}, {'value': '12', 'groupId': 'BG003'}, {'value': '52', 'groupId': 'BG004'}]}, {'title': 'Male', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '10', 'groupId': 'BG003'}, {'value': '35', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '9', 'groupId': 'BG004'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '19', 'groupId': 'BG000'}, {'value': '19', 'groupId': 'BG001'}, {'value': '19', 'groupId': 'BG002'}, {'value': '21', 'groupId': 'BG003'}, {'value': '78', 'groupId': 'BG004'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '10', 'groupId': 'BG004'}]}, {'title': 'White', 'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '20', 'groupId': 'BG001'}, {'value': '19', 'groupId': 'BG002'}, {'value': '18', 'groupId': 'BG003'}, {'value': '77', 'groupId': 'BG004'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '21', 'groupId': 'BG000'}, {'value': '22', 'groupId': 'BG001'}, {'value': '22', 'groupId': 'BG002'}, {'value': '22', 'groupId': 'BG003'}, {'value': '87', 'groupId': 'BG004'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Intraocular pressure', 'classes': [{'categories': [{'title': '≤26 mmHg', 'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '14', 'groupId': 'BG001'}, {'value': '15', 'groupId': 'BG002'}, {'value': '15', 'groupId': 'BG003'}, {'value': '58', 'groupId': 'BG004'}]}, {'title': '>26 mmHg', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '7', 'groupId': 'BG003'}, {'value': '29', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'measured in mmHg\n\nRandomization stratum for IOP (≤26 mmHg and \\>26 mmHg)', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-01-08', 'size': 1357287, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2021-06-21T00:35', 'hasProtocol': True}, {'date': '2018-09-06', 'size': 1445243, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2021-06-21T00:36', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR'], 'maskingDescription': 'Double-masked containers'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Double-masked, parallel'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 87}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-03-15', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-06', 'dispFirstSubmitDate': '2020-07-16', 'completionDateStruct': {'date': '2018-08-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-06-23', 'studyFirstSubmitDate': '2018-02-26', 'dispFirstSubmitQcDate': '2021-07-12', 'resultsFirstSubmitDate': '2021-06-21', 'studyFirstSubmitQcDate': '2018-02-26', 'dispFirstPostDateStruct': {'date': '2021-08-02', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2022-07-12', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2021-07-12', 'studyFirstPostDateStruct': {'date': '2018-03-02', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2021-08-02', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-08-15', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Intraocular Pressure (IOP)', 'timeFrame': 'Baseline and 28 days', 'description': 'Mean change in IOP from baseline on Day 28 (Time 0 + 4h)'}], 'secondaryOutcomes': [{'measure': 'Number of Participants With Adverse Events', 'timeFrame': '28 days', 'description': 'Number of participants with treatment-emergent adverse events'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['glaucoma'], 'conditions': ['Glaucoma, Open-Angle']}, 'referencesModule': {'references': [{'pmid': '36055467', 'type': 'DERIVED', 'citation': 'Hartman PJ, Cooke DL, Hsu HH, Stewart J, Sumi K, Yoshida Y, Hidaka H, Novack GD. Phase Ⅰ/Ⅱ, Double-Masked, Randomized, Vehicle-Controlled Study of H-1337 Ophthalmic Solution for Glaucoma and Ocular Hypertension. Ophthalmol Glaucoma. 2023 Mar-Apr;6(2):198-205. doi: 10.1016/j.ogla.2022.08.015. Epub 2022 Aug 31.'}]}, 'descriptionModule': {'briefSummary': 'The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with elevated intraocular pressure (IOP).', 'detailedDescription': "Study ALY337-201 will be a double-masked, randomized, placebo-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of H-1337 ophthalmic solution in subjects with ocular hypertension (OHT) or open angle glaucoma.\n\nDuring screening, subjects who meet the preliminary inclusion/exclusion criteria will discontinue use of their ocular hypotensive therapy during the washout period. The washout duration will be dependent on the subject's pre-study ocular hypotensive therapy. Starting on Day 0, those who continue to meet the inclusions/exclusion criteria and the diurnal IOP criteria will be randomized into one of the treatments arms and dosing will be initiated, continuing for 28 days."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '99 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. 18 years of age or older.\n2. Diagnosis of bilateral primary open angle glaucoma or ocular hypertension.\n3. One qualifying IOP criteria after washout:\n\n • Baseline (Day 0) at T0 (T0 = 8 am ± 30 min) IOP ≥ 23 mmHg in the study eye.\n4. IOP criteria after washout ≤ 32 mmHg oculus uterque (OU) at all time points.\n5. Best-corrected visual acuity (BCVA) in both eyes of 20/200 or better on Snellen, equivalent to + 1.0 log Mar.\n6. Able and willing to sign informed consent, follow study instructions and complete all study visits.\n7. As applicable, must be willing to discontinue the use of all ocular hypotensive medication(s) in both eyes prior to receiving the study medication and for the entire course of the study.\n8. Able to self-administer or have a caretaker administer study eye drops.\n\nExclusion Criteria:\n\nOphthalmic:\n\nExclude subjects with:\n\n1. Closed or very narrow angles (Grade 0-1) (see Section 5, gonioscopy) or those the investigator judges as occludable and/or with evidence of peripheral anterior synechiae (PAS) ≥ 180 degrees by gonioscopy within 6 months prior to Screening Visit in either eye. (Patent laser iridotomy with Grade 1-2 angles is acceptable in either eye, providing the PAS criteria are still met).\n2. Previous glaucoma intraocular surgery in either eye. Prior laser trabeculoplasty (ALT or SLT) in either eye is allowed if performed more than 6 months prior to Screening Visit.\n3. Any non-glaucoma intraocular surgery within 3 months prior to Screening Visit in either eye.\n4. Intraocular laser surgery such as laser capsulotomy, laser iridotomy, and/or retinal laser within 1 month prior to Screening Visit in either eye.\n5. Significant media opacity in either eye that would impede adequate posterior segment examination.\n6. Contraindications to pupil dilation in either eye.\n7. Other forms of glaucoma such as primary congenital, juvenile onset, chronic angle closure, and secondary glaucoma of any type including steroid-induced, inflammation-induced, or exfoliation glaucoma in either eye. Pigment dispersion syndrome/glaucoma is permitted in either eye.\n8. Clinically significant corneal dystrophy, epithelial or endothelial disease, corneal irregularities or scarring that, in the investigator's judgment, would impede an accurate measurement of IOP or visualization of intraocular anatomy in the study eye.\n9. History of refractive surgery in either eye (i.e., radial keratotomy, photorefractive keratectomy, LASIK).\n10. History of corneal cross-linking procedure in either eye.\n11. Unwillingness to be contact lens free during study participation.\n12. Any history of uveitis, keratitis, or scleritis in either eye.\n13. Any history of penetrating ocular trauma in either eye.\n14. History within 3 months prior to Screening Visit of clinically significant moderate or severe chronic or active blepharitis, ocular dermatitis, or recent ocular conjunctivitis and/or ocular inflammation in either eye. Mild blepharitis, hyperemia (due to prostaglandin use) and/or blepharitis, and/or mild inactive seasonal allergic conjunctivitis and non-infective dermatitis are acceptable.\n15. Corneal thickness \\< 480 or \\> 620 µm in the study eye. Pachymetry measurement within 6 months prior to Screening Visit is acceptable.\n16. Advanced or severe glaucoma with progressive visual field loss and/or optic nerve changes in either eye that, in the investigator's best judgment, prevent safe withdrawal from treatment for the time periods required in this protocol.\n17. Progressive retinal (including, but not limited to worsening dry age-related macular degeneration (AMD), presence of active wet AMD, or unstable diabetic retinopathy) or optic nerve disease in either eye from any cause other than glaucoma.\n18. Any prior intravitreal steroid injection in either eye.\n19. Sub-tenon's, sub-conjunctival or periocular steroid injections within the 6 months prior to Screening Visit in either eye.\n20. Any use of ocular topical corticosteroids in either eye within 7 days, or chronic (as determined by the investigator) topical steroids within 28 days prior to Baseline and ensuing trial participation.\n21. Known hypersensitivity to any component of the H-1337 formulation, including benzalkonium chloride, or to topical anesthetics or diagnostic drops used during the study.\n22. Any ocular, condition that, in the investigator's judgment, could prevent the subject from safe participation the study.\n23. Planned ocular surgery or intraocular injection procedure in either eye during study participation.\n\n General/Systemic:\n24. Participation in a clinical study with use of any investigational drug or treatment within 30 days prior to Baseline (Day 0).\n25. Clinically significant abnormalities in: laboratory tests, physical examination, vital signs and/or ECG at Screening Visit. If in the investigator's judgment a subject with clinically significant abnormalities is appropriate for enrollment in the study, a discussion between the investigator and the Medical Monitor must occur and be documented prior to enrollment of this subject in the study.\n26. Clinically significant systemic, psychiatric or psychological disease (for example, renal, hepatic, uncontrolled diabetes, uncontrolled blood pressure, autoimmune disorders, psychiatric disorders, endocrine disorders, or any other disorders) or dependency which, in the investigator's judgment, would be unsafe and interfere with interpretation of the study results or the subject's ability to comply with the study requirements.\n27. Anticipated changes or initiation of medications which might affect IOP and/or systemic blood pressure within 7 days prior to Baseline/Day 0 (e.g., oral anti-hypertensives such as sympathomimetic agents, beta-adrenergic blocking agents, alpha agonists, alpha adrenergic blocking agents, calcium channel blockers, angiotensin converting enzyme inhibitors; \\[diuretics are allowed\\]), and 2 months prior to Baseline/Day 0 for corticosteroids (i.e., oral, nasal, topical \\[dermal, mucosal\\], and/or inhaled corticosteroids). If there are no further anticipated changes in medications that could affect IOP and/or systemic blood pressure, then once the subject is stable on their new dose of medication for the required time period, the subject may complete the Baseline Visit, assuming that all other screening requirements are met. Medications used on an adjustable or sliding scale based on testing results are allowed.\n28. Known history of Hepatitis B + C, HIV+, or AIDS and/or inadequate venous access.\n29. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative serum pregnancy test result at Screening Visit and a negative urine and serum pregnancy test at Baseline (Day 0) prior to randomization in the study and must not intend to become pregnant during the study.\n30. History of drug or alcohol abuse within the last 5 years.\n31. Related to site study staff and/or site employees."}, 'identificationModule': {'nctId': 'NCT03452033', 'briefTitle': 'H-1337 Ophthalmic Solution Phase 1/2', 'organization': {'class': 'INDUSTRY', 'fullName': 'Allysta Pharmaceutical'}, 'officialTitle': 'A Phase 1/2a Randomized, Double-masked, Placebo Controlled, Dose-ranging Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension', 'orgStudyIdInfo': {'id': 'ALY337-201'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'H-1337 Placebo', 'description': 'H-1337 Placebo', 'interventionNames': ['Drug: H-1337 Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'H-1337 [1]', 'description': 'H-1337 \\[1\\]', 'interventionNames': ['Drug: H-1337 [1]']}, {'type': 'EXPERIMENTAL', 'label': 'H-1337 [2]', 'description': 'H-1337 \\[2\\]', 'interventionNames': ['Drug: H-1337 [2]']}, {'type': 'EXPERIMENTAL', 'label': 'H-1337 [3]', 'description': 'H-1337 \\[3\\]', 'interventionNames': ['Drug: H-1337 [3]']}], 'interventions': [{'name': 'H-1337 Placebo', 'type': 'DRUG', 'otherNames': ['Vehicle'], 'description': 'H-1337 Placebo Vehicle', 'armGroupLabels': ['H-1337 Placebo']}, {'name': 'H-1337 [1]', 'type': 'DRUG', 'otherNames': ['H-1337 conc 1'], 'description': 'H-1337 Ophthalmic Solution Concentration 1', 'armGroupLabels': ['H-1337 [1]']}, {'name': 'H-1337 [2]', 'type': 'DRUG', 'otherNames': ['H-1337 conc 2'], 'description': 'H-1337 Ophthalmic Solution Concentration 2', 'armGroupLabels': ['H-1337 [2]']}, {'name': 'H-1337 [3]', 'type': 'DRUG', 'otherNames': ['H-1337 conc 3'], 'description': 'H-1337 Ophthalmic Solution Concentration 3', 'armGroupLabels': ['H-1337 [3]']}]}, 'contactsLocationsModule': {'locations': [{'zip': '29445', 'city': 'Goose Creek', 'state': 'South Carolina', 'country': 'United States', 'facility': 'PRN', 'geoPoint': {'lat': 32.98101, 'lon': -80.03259}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'No plan at current.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Allysta Pharmaceutical', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}